The levels of several smooth muscle cell-associated proteins decreased in AD ACA relative to controls, specifically perlecan, myosin light polypeptide 6 and myosin regulatory light polypeptide 9, and leiomodin-1 (FDR < 0.05) (Fig. 7). This evidence concerns the gene MYL6 and Alzheimer disease.